Albert Császár

2.2k total citations
50 papers, 1.1k citations indexed

About

Albert Császár is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Immunology. According to data from OpenAlex, Albert Császár has authored 50 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Surgery, 14 papers in Endocrinology, Diabetes and Metabolism and 10 papers in Immunology. Recurrent topics in Albert Császár's work include Lipoproteins and Cardiovascular Health (19 papers), Cancer, Lipids, and Metabolism (10 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers). Albert Császár is often cited by papers focused on Lipoproteins and Cardiovascular Health (19 papers), Cancer, Lipids, and Metabolism (10 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers). Albert Császár collaborates with scholars based in Hungary, Germany and Austria. Albert Császár's co-authors include Csaba Szalai, Zoltán Prohászka, J. Duba, Ákos Kalina, T Szabó, Laura Horváth, Bálint Nagy, László Romics, George Füst and István Karádi and has published in prestigious journals such as Stroke, Biological Psychiatry and Journal of Lipid Research.

In The Last Decade

Albert Császár

49 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Albert Császár Hungary 17 300 268 261 233 199 50 1.1k
D Schönitzer Austria 21 369 1.2× 300 1.1× 203 0.8× 127 0.5× 212 1.1× 46 1.5k
Christine K. Abrass United States 24 218 0.7× 233 0.9× 434 1.7× 246 1.1× 64 0.3× 44 1.6k
Takuji Hayashi Japan 23 148 0.5× 391 1.5× 246 0.9× 128 0.5× 326 1.6× 64 1.5k
Joris Grond Netherlands 26 207 0.7× 395 1.5× 359 1.4× 98 0.4× 150 0.8× 53 1.7k
V. Bonnevie‐Nielsen Denmark 17 214 0.7× 269 1.0× 309 1.2× 279 1.2× 90 0.5× 39 1.1k
Satoshi Murata Japan 21 296 1.0× 387 1.4× 294 1.1× 185 0.8× 478 2.4× 101 1.5k
H. P. Schwarz Austria 23 377 1.3× 160 0.6× 335 1.3× 139 0.6× 86 0.4× 43 1.9k
Mark K. Wedel United States 19 221 0.7× 537 2.0× 434 1.7× 269 1.2× 93 0.5× 30 1.6k
L Capron France 19 168 0.6× 257 1.0× 304 1.2× 267 1.1× 48 0.2× 83 1.3k
Stephen I‐Hong Hsu United States 22 190 0.6× 127 0.5× 416 1.6× 82 0.4× 337 1.7× 39 1.5k

Countries citing papers authored by Albert Császár

Since Specialization
Citations

This map shows the geographic impact of Albert Császár's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Császár with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Császár more than expected).

Fields of papers citing papers by Albert Császár

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albert Császár. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Császár. The network helps show where Albert Császár may publish in the future.

Co-authorship network of co-authors of Albert Császár

This figure shows the co-authorship network connecting the top 25 collaborators of Albert Császár. A scholar is included among the top collaborators of Albert Császár based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert Császár. Albert Császár is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Farnier, Michel, Jean Ducobu, Armin Steinmetz, et al.. (2012). Safety of a Fixed-Dose Combination of Fenofibrate/Pravastatin 160 mg/40 mg in Patients with Mixed Hyperlipidaemia. Clinical Drug Investigation. 32(4). 281–291. 8 indexed citations
2.
Császár, Albert, et al.. (2012). Correlations between prescription of anti-hypertensive medication and mortality due to stroke. BMC Cardiovascular Disorders. 12(1). 15–15. 7 indexed citations
3.
Balogh, Sándor, et al.. (2010). Continued improvement of cardiovascular mortality in Hungary - impact of increased cardio-metabolic prescriptions. BMC Public Health. 10(1). 422–422. 14 indexed citations
4.
Balogh, Sandor A., István Kiss, & Albert Császár. (2009). Toll-Like Receptors: Link between “Danger” Ligands and Plaque Instability. Current Drug Targets. 10(6). 513–518. 13 indexed citations
5.
Reiber, István, et al.. (2003). Postprandial triglyceride levels in familial combined hyperlipidemia. The role of apolipoprotein E and lipoprotein lipase polymorphisms. The Journal of Nutritional Biochemistry. 14(7). 394–400. 11 indexed citations
6.
Komlósi, Katalin, Judit Bene, Manju Ghosh, et al.. (2003). Search for Factor V Arg<sup>306</sup> Cambridge and Hong Kong Mutations in Mixed Hungarian Population Samples. Acta Haematologica. 110(4). 220–222. 2 indexed citations
7.
Kalina, Ákos, Csaba Szalai, Zoltán Prohászka, István Reiber, & Albert Császár. (2002). Association of plasma lipid levels with apolipoprotein E polymorphism in Type 2 diabetes. Diabetes Research and Clinical Practice. 56(1). 63–68. 15 indexed citations
8.
Császár, Albert, et al.. (2001). Receptor polymorphisms and diseases. European Journal of Pharmacology. 414(1). 9–22. 26 indexed citations
9.
10.
11.
Várkonyi, Judit, Attila Zalatnai, József Tı́már, et al.. (2000). Secondary Cutaneous Infiltration in B Cell Chronic Lymphocytic Leukemia. Acta Haematologica. 103(2). 116–121. 9 indexed citations
12.
Halmos, Balázs, Péter L. Lakatos, Stefan Barlage, et al.. (2000). Association of Primary Biliary Cirrhosis with Vitamin D Receptor BsmI Genotype Polymorphism in a Hungarian Population. Digestive Diseases and Sciences. 45(6). 1091–1095. 43 indexed citations
13.
Prohászka, Zoltán, J. Duba, Gabriella Lakos, et al.. (1999). Antibodies against human heat-shock protein (hsp) 60 and mycobacterial hsp65 differ in their antigen specificity and complement-activating ability. International Immunology. 11(9). 1363–1370. 51 indexed citations
14.
Szalai, Csaba, Albert Császár, A Czinner, et al.. (1999). Chemokine Receptor CCR2 and CCR5 Polymorphisms in Children with Insulin-Dependent Diabetes Mellitus. Pediatric Research. 46(1). 82–84. 48 indexed citations
15.
Zsurka, Gábor, János Kálmán, Anna Juhász, et al.. (1998). No mitochondrial haplotype was found to increase risk for alzheimer’s disease. Biological Psychiatry. 44(5). 371–373. 24 indexed citations
16.
Kálmán, János, Anna Juhász, Albert Császár, et al.. (1998). Increased apolipoprotein E4 allele frequency is associated with vascular dementia in the Hungarian population. Acta Neurologica Scandinavica. 98(3). 166–168. 27 indexed citations
17.
Szombathy, Tamás, et al.. (1998). Association of angiotensin II type 1 receptor polymorphism with resistant essential hypertension. Clinica Chimica Acta. 269(1). 91–100. 49 indexed citations
18.
Romics, László, et al.. (1996). Lipoprotein(a) concentration and phenotypes in primary biliary cirrhosis. Clinica Chimica Acta. 255(2). 165–171. 6 indexed citations
19.
Császár, Albert, et al.. (1995). High lipoprotein(a) levels with predominance of high molecular weight apo(a) isoforms in patients with pulmonary embolism. European Journal of Clinical Investigation. 25(5). 368–370. 14 indexed citations
20.
Császár, Albert, et al.. (1991). [Distribution of apolipoprotein A I and B in the blood according to age and gender, as well as their relation to blood cholesterol levels in the Hungarian blood donor population].. PubMed. 132(33). 1795–800. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D Schönitzer Breakdown of academic impact, for papers by Christine K. Abrass Breakdown of academic impact, for papers by Takuji Hayashi Breakdown of academic impact, for papers by Joris Grond Breakdown of academic impact, for papers by V. Bonnevie‐Nielsen Breakdown of academic impact, for papers by Satoshi Murata Breakdown of academic impact, for papers by H. P. Schwarz Breakdown of academic impact, for papers by Mark K. Wedel Breakdown of academic impact, for papers by L Capron Breakdown of academic impact, for papers by Stephen I‐Hong Hsu
Rankless by CCL
2026